ATE522209T1 - Verwendung von 4-oxobutansäure-derivaten bei der behandlung von mit immunologischen leiden verbundenen erkrankungen - Google Patents

Verwendung von 4-oxobutansäure-derivaten bei der behandlung von mit immunologischen leiden verbundenen erkrankungen

Info

Publication number
ATE522209T1
ATE522209T1 AT08856548T AT08856548T ATE522209T1 AT E522209 T1 ATE522209 T1 AT E522209T1 AT 08856548 T AT08856548 T AT 08856548T AT 08856548 T AT08856548 T AT 08856548T AT E522209 T1 ATE522209 T1 AT E522209T1
Authority
AT
Austria
Prior art keywords
oxobuutanic
treatment
acid derivatives
diseases associated
immunological conditions
Prior art date
Application number
AT08856548T
Other languages
English (en)
Inventor
Valerie Autier
Roland Fabregue
Patrick Miossec
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE522209T1 publication Critical patent/ATE522209T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08856548T 2007-12-03 2008-11-06 Verwendung von 4-oxobutansäure-derivaten bei der behandlung von mit immunologischen leiden verbundenen erkrankungen ATE522209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291449 2007-12-03
PCT/EP2008/009384 WO2009071161A1 (en) 2007-12-03 2008-11-06 Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders

Publications (1)

Publication Number Publication Date
ATE522209T1 true ATE522209T1 (de) 2011-09-15

Family

ID=40328337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08856548T ATE522209T1 (de) 2007-12-03 2008-11-06 Verwendung von 4-oxobutansäure-derivaten bei der behandlung von mit immunologischen leiden verbundenen erkrankungen

Country Status (10)

Country Link
US (1) US20100273872A1 (de)
EP (1) EP2214659B1 (de)
JP (1) JP2011505393A (de)
AR (1) AR069549A1 (de)
AT (1) ATE522209T1 (de)
AU (1) AU2008333635A1 (de)
CA (1) CA2707585A1 (de)
ES (1) ES2368692T3 (de)
IL (1) IL206128A0 (de)
WO (1) WO2009071161A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160108031A1 (en) * 2013-04-30 2016-04-21 Heinrich-Heine-Universitat Dusseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
FR2752422B1 (fr) 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AU4229499A (en) * 1998-07-30 2000-02-21 Warner-Lambert Company Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
WO2003010135A1 (en) * 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Novel phenylpropionic acid derivatives
FR2832925B1 (fr) 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
EP1369114A1 (de) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Benutzung von Tryptophanmetaboliten als pharmazeutische Wirkstoffe
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
KR20050034922A (ko) * 2003-10-10 2005-04-15 주식회사 엘지생명과학 2-알킬-4-옥소부타노일 그룹을 함유하는 케스페이즈저해제 및 그의 약제학적 조성물
WO2007081878A2 (en) * 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells

Also Published As

Publication number Publication date
IL206128A0 (en) 2010-11-30
US20100273872A1 (en) 2010-10-28
JP2011505393A (ja) 2011-02-24
EP2214659A1 (de) 2010-08-11
AU2008333635A1 (en) 2009-06-11
ES2368692T3 (es) 2011-11-21
EP2214659B1 (de) 2011-08-31
CA2707585A1 (en) 2009-06-11
WO2009071161A1 (en) 2009-06-11
AR069549A1 (es) 2010-02-03

Similar Documents

Publication Publication Date Title
CY2024025I2 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4- ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ
EP2249861A4 (de) Behandlung von neurodegenerativen erkrankungen mit progranulin (pgrn)
DK2375907T3 (da) Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
EP2288324A4 (de) Saugfähiger hygieneartikel mit einweglasche
CO6751293A2 (es) Derivados heterocíclicos novedosos y su uso en e tratamiento de trastornos neurológicos
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
EP2060040A4 (de) Verwendung von satztokens in transaktionen
DE602007007146D1 (de) Verfahren zur Herstellung von Müsliriegeln mit verbesserter Konsistenz
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
EP2278999C0 (de) Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
BRPI0906387A2 (pt) Anticorpos alfa 5 - beta 1 e seus usos
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE477798T1 (de) Verwendung von agomelatin zur herstellung von medikamenten zur behandlung der generalisierten angststörung
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
EP2418961A4 (de) Milch-oligosaccharid-zusammensetzung und ihre verwendung bei der behandlung von infektionen bei tieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties